Status:
COMPLETED
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Autoimmune Diseases
Checkpoint Inhibitor
Eligibility:
All Genders
18+ years
Brief Summary
Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in ...
Eligibility Criteria
Inclusion
- 18 years or older
- Patients with cancer
- Patients with autoimmune disease
- Treated at HeCOG-affiliated Departments of Oncology
- Early-stage or metastatic
Exclusion
- diagnosis of the autoimmune disease after initiation of immunotherapy
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT04805099
Start Date
November 1 2020
End Date
February 28 2021
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hellenic Oncology Cooperative Group
Athens, Greece